Adverum to Discuss LUNA Phase 2 Data in Webcast on Feb 8

Adverum Biotechnologies, a clinical-stage company focused on gene therapy for prevalent eye diseases, is set to present early findings from its LUNA Phase 2 study. The study investigates ixoberogene soroparvovec (Ixo-vec) as a potential treatment for wet age-related macular degeneration (AMD). The preliminary data on safety and efficacy will be shared during a webcast on February 8, 2024, at 8:00am ET. Szilard Kiss, M.D., a key investigator in the study and a professor at Weill Cornell Medical College, will be part of the webcast.

The LUNA study, which reached full enrollment in August 2023, will also be highlighted at the 47th Annual Meeting of the Macula Society. The presentation, titled "Ixoberogene soroparvovec (Ixo-vec) Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration: Preliminary Results from the Phase 2 LUNA Study," will be delivered by Arshad M. Khanani, M.D., M.A., FASRS, on the same day at 10:56am ET.

Adverum is committed to developing a single-administration gene therapy that could serve as a long-term solution for patients with wet AMD, reducing the need for frequent eye injections. The company's proprietary intravitreal platform aims to provide durable treatments that can be administered in a clinical setting, improving the standard of care and potentially preserving vision on a global scale.

The webcast and conference call will delve into the details of the LUNA study's initial results, offering insights into the progress of ixoberogene soroparvovec as a novel gene therapy candidate. The presentation will be accessible on Adverum’s website following the event, under the News and Publications section.

Adverum Biotechnologies is dedicated to transforming the treatment landscape for debilitating ocular diseases, with the goal of creating a significant societal impact by restoring vision and preventing blindness. The company's innovative approach to gene therapy reflects its aspiration to establish new benchmarks in ocular care.